Transfluthrin does not elicit electroantennogram in <i>Ae</i>. <i>aegypti</i>. by Felipe Andreazza (11098928)

A decreased yield of RNP1, RNP2 and RNP5 formation in the presence of protein aGAR1 is counteracted by RNA-S by Bruno Charpentier (9519)

Expression of Aβ42 decreases K_v4 protein and currents in the intact brain. by Yong Ping (233004)

ALVAC-HIV elicits V2, V3, and CD4 inducible (CD4i) binding antibody responses. by LaTonya D. Williams (3140490)

Delayed boosting with ALVAC-HIV/AIDSVAX B/E or AIDSVAX B/E increases breadth of Env-specific IgG response. by LaTonya D. Williams (3140490)

Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant by Yingxia Wen (2455015)

Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study by Robert Molokie (4419409)

“…Total hemoglobin increased by 1.2–1.9 g/dL (<i>P</i> = 0.01) as reticulocytes simultaneously decreased; that is, better quality and efficiency of HbF-enriched erythropoiesis elevated hemoglobin using fewer reticulocytes. …”

A Pilot Randomized Placebo Controlled Trial of Electroacupuncture for Women with Pure Stress Urinary Incontinence by Huanfang Xu (2558446)

“…Adverse events (AEs) were monitored throughout the trial.</p><p>Results</p><p>The median decrease from baseline of urine leakage measured by the 1-hour pad test was 2.5 g [interquartile range (IQR): 1.80–14.6 in the EA group, which was greater than the median decrease of 0.05 g (IQR: -2.80–+0.50) in the sham EA group after 6 weeks (p<0.01). …”

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study by David N. Franz (822882)

Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial by Silvana Sekuloski (209827)

“…Participants were randomized 4:1 to receive the vaccine candidate (N = 8) or placebo (N = 2). …”

Discrete, Solvent-Free Alkaline-Earth Metal Cations: Metal···Fluorine Interactions and ROP Catalytic Activity by Yann Sarazin (1588777)

“…PLLAs with <i>M</i>_n up to 35 000 g·mol^–1 were produced in a very controlled fashion (<i>M</i>_w/<i>M</i>_n ≈ 1.10–1.20) and without epimerization. …”

Protein synthesis inhibition induces <i>mtl-1</i> expression in response to deregulated Ca²⁺ homeostasis. by Hans M. Dalton (5532668)

“…<p>(<i>A</i>-<i>B</i>) Organismal expression of <i>mtl-1</i> is increased while <i>mtl-2</i> is decreased in response to protein synthesis inhibition generated by RNAi in all cells (solid bars), hypodermal-specific RNAi (Hyp), or the germline-specific RNAi (Ger), but not the intestine-specific RNAi (Int) (<i>A</i>); this expression is more pronounced after 5 days (120hr) in the arrested state (<i>B</i>) (3 biological replicates). …”

Table 1_Optimal fertilizer rate and sowing density can improve oat quality, yield and N and P comprehensive efficiency in the Loess Plateau of China.docx by Ruochen Zhang (3434996)

“…The three sowing densities (SD, L: 75 kg/ha; M: 150 kg/ha; H: 225 kg/ha) were coupled with six fertilizer rates (FR, N0P0: no fertilization; N2: 100 N kg/ha; P2: 90 P kg/ha; N1P2: 50 N kg/ha, 90 P kg/ha; N2P1: 100 N kg/ha, 45 P kg/ha; N2P2: 100 N kg/ha, 90 P kg/ha). …”

DataSheet1_A phase 1 study of dimdazenil to evaluate the pharmacokinetics, food effect and safety in Chinese healthy subjects.pdf by Fei Wang (19534)

“…The most treatment-emergent AEs were dizziness (n = 4, 8.2%), hyperuricemia (n = 2, 6.1%), upper respiratory tract infection (n = 2, 6.1%), diastolic blood pressure decreased (n = 2, 6.1%), blood TG increased (n = 2, 6.1%) and RBC urine positive (n = 2, 6.1%). …”

Table1_The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database.pdf by Xiaogan Wang (4978514)

Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials by Francesco Giorgino (385654)

“…Baseline characteristics, change from baseline to Week 40/42 for efficacy parameters, and gastrointestinal adverse events (GI AEs) were described and analyzed by early response in FSG (SURPASS-1 to -4; N=3,676) or weight (SURPASS-1 to -5; N=4,121) in the efficacy and safety analysis set, respectively. …”

Estimating germline maintenance. by Mareike Koppik (4489318)

Table1_A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database.... by Huanying Xu (17813399)

Synthesis and Biological Evaluation of Peripheral 5HT_2B Antagonists for Liver Fibrosis by Jihyeon Yoon (8705706)

Synthesis and Biological Evaluation of Peripheral 5HT_2B Antagonists for Liver Fibrosis by Jihyeon Yoon (8705706)